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Background: Intraoperative radiotherapy (IORT) is a new treatment approach for early stage breast cancer. This
study reports on the effects of IORT on radiation-related quality of life (QoL) parameters.
Methods: Two hundred and thirty women with stage I-III breast cancer (age, 31 to 84 years) were entered into the
study. A single-center subgroup of 87 women from the two arms of the randomized phase III trial TARGIT-A
(TARGeted Intra-operative radioTherapy versus whole breast radiotherapy for breast cancer) was analyzed.
Furthermore, results were compared to non-randomized control groups: n = 90 receiving IORT as a tumor bed
boost followed by external beam whole breast radiotherapy (EBRT) outside of TARGIT-A (IORT-boost), and n = 53
treated with EBRT followed by an external-beam boost (EBRT-boost). QoL was collected using the European
Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 (QLQ-C30) and BR23 (QLQ-
BR23). The mean follow-up period in the TARGIT-A groups was 32 versus 39 months in the non-randomized control
groups.
Results: Patients receiving IORT alone reported less general pain (21.3 points), breast (7.0 points) and arm (15.1
points) symptoms, and better role functioning (78.7 points) as patients receiving EBRT (40.9; 19.0; 32.8; and 60.5
points, respectively, P < 0.01). Patients receiving IORT alone also had fewer breast symptoms than TARGIT-A patients
receiving IORT followed by EBRT for high risk features on final pathology (IORT-EBRT; 7.0 versus 29.7 points,
P < 0.01). There were no significant differences between TARGIT-A patients receiving IORT-EBRT compared to
non-randomized IORT-boost or EBRT-boost patients and patients receiving EBRT without a boost.
Conclusions: In the randomized setting, important radiation-related QoL parameters after IORT were superior to
EBRT. Non-randomized comparisons showed equivalent parameters in the IORT-EBRT group and the control groups.
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Intraoperative radiotherapy (IORT) is a new treatment
option for women with early stage operable breast can-
cer, and it is increasingly used in clinical practice. In
2000, the international randomized phase III trial
TARGIT-A (NCT00983684; TARGeted Intra-operative
radioTherapy versus whole breast radiotherapy for breast
cancer) was started to investigate the non-inferiority of
targeted intraoperative radiotherapy (IORT) given in a
single dose to the tumour bed during breast-conserving
surgery (BCS) as compared to conventional external
beam whole breast radiotherapy (EBRT) in early stage
breast cancer. In the presence of risk factors identified in
the final pathology (invasive lobular carcinoma, exten-
sive intraductal component, involved margins, lympho-
vascular invasion) postoperative EBRT is added after
IORT per protocol (IORT-EBRT). The first analysis of
the trial, published in June 2010, showed a 4 year local
recurrence rate of about 1% and a clinically relevant tox-
icity rate of about 3% in both arms [1,2].
The primary aim of the present analysis was to assess
radiation-related QoL parameters in the first 123 women
from a single center participating in the TARGIT-A trial.
The secondary aim was to compare TARGIT-A IORT-
EBRT patients with two non-randomized control groups
of patients treated with (i) IORT as a tumor bed boost
followed by EBRT outside of TARGIT-A (IORT-boost)
or (ii) EBRT followed by an external-beam boost to the
tumor bed (EBRT-boost). The primary end points were
the global health status, restrictions in daily activities
(role functioning), and general pain subscales from the
European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire C30
(QLQ-C30, version 3) [3], and the breast symptoms and
arm symptoms subscales from the EORTC Quality of
Life Breast Cancer Module (QLQ-BR23) [4].
Methods
Treatment and patients
This study was a single center cross-sectional analysis.
To qualify for the analysis, patients had to be rando-
mized in the TARGIT-A trial between 2002 and 2009
from the University Medical Centre Mannheim. The full
protocol of TARGIT-A is available online [5].
All eligible TARGIT-A patients were treated as follows
Arm A: IORT with 50 kV X-rays (INTRABEAM™ sys-
tem, Carl Zeiss Surgical, Oberkochen, Germany) deliver-
ing 20 Gy at the applicator surface during BCS (IORT
group). In the presence of risk factors this was followed
by EBRT with 46 Gy in 23 fractions or 50 Gy in 25 frac-
tions to the whole breast (IORT-EBRT group). Arm B:
EBRT with 56 Gy in 28 fractions to the whole breast
postoperatively without boost (EBRT group). The ration-
ale of the EBRT treatment was based on the Germanbreast cancer study group (GBSG) recommendations at
the time of study initiation.
The patients of the control groups outside of
TARGIT-A were treated between 2002 and 2006 at the
same centre. Patients received BCS and either a combin-
ation of 20 Gy IORT and postoperative EBRT of 46 Gy in
23 fractions (IORT-boost group) or postoperative EBRT of
50 Gy in 25 fractions followed by an external-beam boost
to the tumor bed of 16 Gy in 8 fractions (EBRT-boost
group). EBRT was initiated after completion of wound
healing and/or chemotherapy. All patients received sys-
temic therapy according to the St. Gallen consensus
recommendations. Chemotherapy was routinely given be-
fore EBRT. Endocrine therapy was started 8–14 days after
surgery or after completion of chemotherapy.
From June 2002 to February 2009, 88 patients (72%)
out of 123 patients accrued to the TARGIT-A trial at
our center consented to participate in the QoL study.
Forty-six and 42 patients were allocated in the targeted
intraoperative radiotherapy (Arm A, IORT +/− EBRT)
and external beam radiotherapy (Arm B, EBRT) groups,
respectively. Sixteen patients allocated to intraoperative
radiotherapy received intraoperative radiotherapy plus
external beam radiotherapy postoperatively (IORT-EBRT
group). Five patients did not receive IORT: Four patients
were treated with 56 Gy external beam radiotherapy
postoperatively, one patient refused external beam radio-
therapy. All patients received treatment as mentioned
above. The patients in Arm B were treated with 28 x 2
Gy to the whole breast, and none of them received an
additional boost. The mean age at the TARGIT-A entry
was 64.7 years (median 65 years, range, 47 to 84), the
mean follow-up time was 32.1 months (median 25
months, range, 9 to 94).
In addition, this single-center subgroup of patients from
the TARGIT-A trial was compared to patients of our cen-
ter treated with IORT as a tumor bed boost followed by
EBRT outside of TARGIT-A (IORT-boost group), and
patients treated with EBRT followed by an external-beam
boost to the tumor bed (EBRT-boost group). All patients
treated between 2002 and 2006 with 20 Gy IORT as a
tumor bed boost followed by 46/2 Gy EBRT to the whole
breast outside of TARGIT-A were asked to participate in
the IORT-boost control group. 90 patients (96%) out of 94
patients consented to participate. All patients treated with
50/2 Gy EBRT to the whole breast followed by 16/2 Gy
EBRT-boost to the tumor bed between 2005 and 2006
were asked to participate in the EBRT-boost group, and
53 patients (85%) out of 62 patients participated. For these
groups, the mean age at the time of surgery was 56.3 years
(median 56 years, range, 31 to 81), and the follow-up time
was 39.1 months (median 41 months, range, 8 to 64).
Most patients suffered from breast cancer stage I or
stage II. One patient (2%) in the EBRT group, 4 patients
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the EBRT-boost group had breast cancer stage III. At
the time of survey, all patients were disease free. Further
patients’ characteristics are summarized in Table 1. We
compared the patients that participated in the QoL
study with those who declined participation to assess for
sample bias, and there were no differences regarding
demographic and clinical variables (data not shown).
Also compared with patients in the whole TARGIT A
trial [1], TARGIT-A patients in our study had largely
similar demographic and clinical characteristics.
The present study was performed according to the
Declaration of Helsinki principles. All patients were
informed about the study and given the option of par-
ticipating or not. Patients who consented to participate
received mailed questionnaires 8 to 94 months following
treatment. It was the choice of the patient to answer the










Married/partnered 14 58 22 48





0-1 cm 8 32 14 30
1-2 cm 16 64 25 34
> 2 cm 1 4 7 15
Nodal involvement
N0 23 92 36 78
N1 2 9 9 20
> N1 0 0 1 2
ALND 4 16 14 30
Chemotherapy 4 17 5 11
Endocrine therapy 23 96 40 93
Radiotherapy of supra- and infraclavicular nodes 0 0 2 4
Medical comorbidities ≥2b 14 56 37 80
Abbreviations: TARGIT-A, TARGeted Intra-operative radioTherapy versus whole breas
external beam whole breast radiotherapy, ALND, axillary lymph node dissection.
* IORT versus EBRT versus IORT-EBRT.
** IORT-EBRT versus IORT-boost versus EBRT-boost.
a One patient without axillary assessment.
b Coexisting medical conditions were assessed by medical record review and by pa
physical illnesses or injuries that needed long-term treatment.considered as informed consent. To maximize response
rate, patients were reminded by telephone after non-
response.
QoL measures
Quality of life was assessed using two validated question-
naires of the EORTC: the Quality of Life Questionnaire
C30 (QLQ-C30, version 3) and the Breast Cancer Mod-
ule (QLQ-BR23).
The QLQ-C30 measure consists of one global health
status/quality of life scale, five functioning scales (phys-
ical, role, emotional, cognitive, and social), three symp-
tom scales (fatigue, nausea/vomiting, and general pain),
and six single item scales (dyspnea, insomnia, appetite
loss, constipation, diarrhea, and financial impact). The
QLQ-BR23 module consists of two functioning scales
(body image and sexual), three symptom scales (systemic







No. % P* No. % No. % P**
61.8 0.276 60.1 49.9 <0.001
6.0 11.1 9.2
13 81 0.066 58 64 39 76 0.191
0 0 0.185 27 31 31 60 <0.001
35.6 0.641 34.2 47.5 <0.001
19.6 13.7 7.4
3 19 0.376 13 14 6 11 0.414
9 56 49 54 23 43
4 25 28 31 24 45
14 88 0.622 66 73 34 65a 0.253
2 12 20 22 11 21
0 0 4 4 7 13
4 25 0.409 55 61 41 79a <0.001
2 12 0.908 18 20 36 68 <0.001
13 81 0.322 70 78 36 86 0.349
0 0 0.693 7 8 10 19 0.049
11 69 0.091 49 54 9 17 <0.001
t radiotherapy for breast cancer, IORT, intraoperative radiotherapy, EBRT,
tient self-report. A medical comorbidity was defined as having two or more
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spective, and upset by hair loss) specific to breast cancer.
The scoring of both questionnaires was performed
according to the recommended EORTC procedures [6].
All scores can be linearly transformed to a 0–100 point
scale, with higher scores of functioning indicating
greater functioning, i.e. better QoL, and higher scores on
symptoms indicating worse symptoms, i.e. worse QoL.
The time frame for all questions is the situation in the
last week, except for items related to sexual functioning
where a 4-week time frame is taken. Five functioning
and symptom scales of the QLQ-C30/QLQ-BR23 ques-
tionnaires were preselected during the design of this
study, based on a pilot study by our group [7] and rele-
vance for radiation-related QoL in breast cancer: Global
health status, restrictions in daily activities (role func-
tioning), and general pain, breast, and arm symptoms.
Other subscales and items of the QLQ-C30/QLQ-BR23
questionnaires were outside the aim of this study and
are not presented here. The item response rate was be-
tween 96% and 99%.
The Hospital Anxiety and Depression Scale (HADS)
[8], the Functional Assessment of Cancer Therapy-
Fatigue (FACT-F) subscale [9], the Rosenberg Self-
Esteem Scale (RSES) [10], and the Body Image Scale
(BIS) [11] were used to control for differences that may
inherently exist between the treatment groups. The Hos-
pital Anxiety and Depression Scale (HADS) is a ques-
tionnaire for the screening of anxiety and depression in
patients with physical illness. It consists of two sub-
scales: one for anxiety and one for depression. The
Functional Assessment of Cancer Therapy-Fatigue
(FACT-F) subscale assesses fatigue and its impact on
daily activities. The Rosenberg Self-Esteem Scale (RSES)
measures global feelings of self-worth and self-accept-
ance. The Body Image Scale (BIS) is a valid measure of
the affective, cognitive, and behavioral components of
body image in cancer patients. The BIS was constructed
in collaboration with the EORTC Quality of Life Study
Group, and includes the body image subscale of the
QLQ-BR23 module.Table 2 Preselected QoL variables between TARGIT-A patient
Allocated to IORT
Variable Na Mean
Global health statusb 46 61.6
Restrictions in daily activitiesb 46 72.8
General painc 46 29.3
Breast symptomsc 45 17.0
Arm symptomsc 45 24.4
a Number of valid assessments.
b Higher scores are equal to good functioning/good quality of life.
c Higher scores are equal to severe symptoms/worse quality of life.The scores of the HADS, FACT-F, RSES and BIS ques-
tionnaires were summed for each scale. The HADS
scores range from 0 (no anxiety/depression) to 21 (se-
vere anxiety/depression). The range of the FACT-F score
is from 0 (greatest fatigue) to 52 (lowest fatigue). The
RSES score ranges between 10 (low self esteem) and 40
(high self esteem). The BIS score ranges from 0 (best
body image) to 30 (worst body image).
Statistical analysis
Data analyses were performed with the IBM Statistical
Package for Social Sciences software, version 19 (SPSS
Inc., Chicago, IL). All analyses were performed on an
intention-to-treat and as-treated basis. The level of stat-
istical significance was set at 0.01 (0.05/5) to reduce type
I errors in multiple comparisons. Chi-squared tests (or
Fisher’s exact tests), Kruskal-Wallis one-way analyses of
variance, and post-hoc Mann–Whitney U-tests (or uni-
variate analyses of variance and post-hoc Scheffe tests)
were used to compare the treatment groups. Independ-
ent effects of demographic and clinical factors on QoL
were tested using univariate linear regression analysis.
Variables with a p value < 0.05 were further analyzed
with multiple linear regression analysis (stepwise forward
method).
Results
Intention-to-treat (ITT) analysis of randomized patients
from TARGIT-a trial
In the ITT analyses, patients allocated to IORT showed
more professional and other daily activities and fewer
general pain symptoms compared to patients allocated
to EBRT, but none of the P values were below 0.01
(Table 2).
As-treated (AT) analysis of randomized patients from
TARGIT-a trial
The AT analyses demonstrated a significant benefit for
patients treated with IORT alone. Patients receiving
IORT alone reported more professional and other daily
activities (mean 78.7, SD 35.2) compared to patientss allocated to IORT versus EBRT
Allocated to EBRT
SD Na Mean SD P
21.7 40 54.8 19.9 0.183
32.3 41 61.8 29.2 0.055
32.8 42 42.5 33.0 0.048
20.8 42 18.1 20.2 0.629
26.7 40 31.1 27.9 0.279
Figure 1 General pain by treatment group as measured with
the EORTC QLQ-C30. Higher scores are equal to severe symptoms/
worse quality of life. Please note: Univariate regression analysis
revealed no influence of follow-up duration on self-reported pain
symptoms. Abbreviations: SD, standard deviation. * Mann–Whitney
U-test. P = 0.018. ** Mann–Whitney U-test. P = 0.007.
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ences in the global health status subscale were not
observed (IORT, mean 63.6, SD 24.2, EBRT, mean 52.4,
SD 22.1, IORT-EBRT, mean 60.9, SD 19.9; P > 0.01). The
mean scores for the general pain, breast, and arm symp-
tom scales were significantly lower in IORT patients
than EBRT patients (Figures 1, 2, 3). The difference in
breast symptoms between IORT and IORT-EBRT
patients was also significant (Figure 2). Between-group
differences in the HADS, FACT-F, RSES and BIS scores
were not observed (P > 0.01). Table 3 summarizes the
frequencies of moderate or severe breast and arm symp-
toms reported by patients. The most commonly reported
symptoms were moderate or severe pain in the arm orFigure 2 Breast symptoms by treatment group as measured
with the EORTC QLQ-BR23. Higher scores are equal to severe
symptoms/worse quality of life. Please note: Univariate regression
analysis revealed no influence of follow-up duration on self-reported
breast symptoms. * Mann–Whitney U-test. P = 0.021. ** Mann–Whitney
U-test. P = 0.001. *** Mann–Whitney U-test. P < 0.001.shoulder, difficulty in raising or moving arm sideways,
and pain in the area of the affected breast, with no sig-
nificant differences between treatment groups (P > 0.01).
We found only a few associations between demographic
and clinical characteristics and QoL parameters. Figure 4
shows the percentage of variance explained by multiple
linear regression modeling. Having two or more medical
comorbidities was associated with worse global health
status, more restrictions in other daily activities, i.e.
worse role functioning, and more general pain symptoms
(P = 0.004 to 0.043). Breast and arm symptoms were in-
dependently predicted by tumor size > 2 cm (P = 0.003
and 0.002).
Analysis of IORT-EBRT group and Non-randomized
comparison groups (IORT-boost and EBRT-boost)
No differences between IORT-EBRT patients and
IORT-/EBRT-boost patients were found for any of the
QoL comparisons (P > 0.01; Figures 1, 2, 3). Table 4
shows the proportion of variance explained in the QoL
parameters by each of the demographic and clinical vari-
ables. In the multiple linear regression analyses, only
one factor was related to 4 out of the 5 QoL parameters:
having two or more medical comorbidities was asso-
ciated with worse global health status, restrictions in
daily activities, i.e. worse role functioning, more general
pain symptoms, and arm symptoms.
Discussion
The data reported here are the first to examine the
effects of IORT on radiation-related QoL parameters in
women with breast cancer participating in a randomized
trial. Some of our data confirm a previous study by our
group reporting on fewer breast symptoms and lessFigure 3 Arm symptoms by treatment group as measured with
the EORTC QLQ-BR23. Higher scores are equal to severe
symptoms/worse quality of life. Please note: Univariate regression
analysis revealed no influence of follow-up duration on self-reported
arm symptoms. * Mann–Whitney U-test. P = 0.011. ** Mann–Whitney
U-test. P = 0.009.
Table 3 Frequencies of moderate or severe breast and arm symptoms reported by patients in each group (as treated)
TARGIT-A EBRT+boost
Symptoms (moderate/severe) IORT (%) EBRT (%) IORT-EBRT (%) IORT-boost (%) EBRT-boost (%)
Pain in area of affected breast 4/0 11/4 25/13 20/9 11/8
Swelling in area of affected breast 0/0 4/2 7/7 7/10 11/2
Oversensitivity in area of affected breast 4/0 9/7 20/7 20/15 11/8
Skin problems on or in area of affected breast 4/4 9/4 13/6 11/2 4/7
Pain in arm or shoulder 8/8 18/23 33/20 21/15 26/8
Swelling in arm or hand 8/4 9/7 6/6 18/9 19/6
Difficulty in raising or moving arm sideways 20/0 24/12 13/7 16/10 11/8
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IORT as a tumor bed boost followed by EBRT in breast
cancer patients treated outside of the TARGIT-A trial
[7]. In the present study, a single-center subgroup of
patients of the TARGIT-A trial treated with IORT alone
were found to have a significantly better radiation-
related QoL than those treated with EBRT as assessed by
restrictions in daily activities (role functioning), general
pain, breast, and arm symptoms. Patients of the
TARGIT-A trial treated with IORT-EBRT had signifi-
cantly more breast symptoms, and a trend to more gen-
eral pain and arm symptoms compared to patients
receiving IORT alone, but did not differ from patients
treated with an IORT boost or EBRT boost outside of
the TARGIT-A trial or EBRT without a boost. The most
commonly reported symptoms were pain in the arm or
shoulder, difficulty in raising or moving arm sideways,
and pain in the area of the affected breast. It is import-
ant to note that demographic and clinical characteristics
had only a minor influence on the QoL parametersFigure 4 Percentage of variance in the QoL parameters accounted fo
The bars show the percentage of variance explained by multiple linear reg
brackets indicates the percentage of variance explained by each factor. The
negatively related to the QoL parameter.assessed here. In addition, there were no further differ-
ences between the TARGIT-A or boost groups in the
anxiety, depression, fatigue, self-esteem, and body image
scores.
Chronic pain in the breast, axilla, or arm is a clinically
significant problem in approximately 50% of breast can-
cer patients [12,13], and a risk factor for poor long-term
quality of life [14]. Previously identified risk factors in-
clude younger age, adjuvant radiotherapy, and axillary
lymph node dissection [12,15]. In our study, general pain
symptoms were related to the treatment with IORT
(IORT was associated with fewer general pain symp-
toms) as well as the number of medical comorbidities
(having 2 or more medical comorbidities was associated
with more general pain symptoms). Neither younger age
nor axillary lymph node dissection had a significant ef-
fect. Having adjusted for demographic and clinical vari-
ables that were found to differ between the treatment
groups, only IORT was associated with a reduction in
breast and arm symptoms. Consistent with our results,r by demographic and clinical variables for the TARGIT-A group.
ression analysis for the QoL parameters examined. The number in
sign before each term indicates whether the factor was positively or
Table 4 Proportion of variance explained in the QoL parameters by each of the demographic and clinical variables for











Age 3,1%* 2,1% 4,5%* 1% 0,0%
Married/partnered 0,9% 1,6% 1,1% 0,6% 0,3%
Employed 2,4% 3,7%* 4,8%* 0,0% 0,7%
Months since BCS 2,6%* 1,2% 0,3% 1,4% 0,8%
Tumor size 1,3% 0,5% 0,8% 0,2% 0,2%
Nodal involvement 0,6% 0,3% 1,3% 1,3% 0,3%
ALND 1,0% 0,0% 0,0% 0,8% 0,0%
Chemotherapy 3,4%* 3,3%* 4,5%* 0,3% 0,2%
Endocrine therapy 0,0% 0,2% 0,0% 0,7% 0,1%
Radiotherapy of supra- and infraclavicular
nodes
1,0% 0,0% 0,2% 0,6% 0,1%
Medical comorbidities ≥2 15,0%** 11,0%** 17,7%** 0,0% 4,9%*
* p < 0,05 in the univariate analysis.
** p < 0,05 in the univariate and multivariate analyses.
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and arm symptoms between patients receiving EBRT
with or without an external boost to the tumor bed.
Until now there are only few studies investigating
QoL, toxicity and cosmesis after partial breast irradi-
ation. Belkacémi et al. reported a transient decrease in
social/family well-being during the first year and an im-
provement in emotional well-being within the first 24
months after HDR brachytherapy [16]. A superior body
image perception was seen after intra- and postoperative
interstitial brachytherapy as compared to EBRT [17],
and IORT was found to be associated with excellent
QoL and few symptoms [18].
The strengths of our study are that it is based on a
randomized trial combined with an assessment of vari-
ous demographic and clinical characteristics, the use of
validated disease-specific QoL questionnaires, and the
analysis of alternative boost techniques. The main limi-
tation of our study is that it is a cross-sectional study
that provided only one estimate of radiation-related QoL
variables. Also, the cross-sectional design does not allow
drawing conclusions regarding causality, but can de-
scribe factors associated with self-reported QoL out-
comes. However, our study offers precise estimates
regarding self-reported general pain, breast, and arm
symptoms and associated factors following radiotherapy
with IORT +/− EBRT or EBRT+/− EBRT boost.
Conclusions
In conclusion, our study is the first in which self-
reported QoL symptoms have identified differences be-
tween IORT and EBRT. In the randomized setting, im-
portant radiation-related QoL parameters after IORT
alone were superior to EBRT. IORT patients reportedless pain, breast, and arm symptoms, and fewer restric-
tions in daily activities compared to EBRT patients.
IORT-EBRT patients showed a trend to more pain,
breast, and arm symptoms compared to IORT alone
patients, but did not differ from patients treated with an
IORT or EBRT boost outside of the TARGIT trial or
EBRT without a boost. In the future, we will extend the
sample size and the follow-up time, and we will assess if
subjective quality of life scores, objective toxicity scores,
and cosmesis are correlated with each other.
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